Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 478 adults with psoriasis across three groups: one group received bimekizumab every four weeks and then switched to every four or eight weeks (161 people), a second group received bimekizumab every four weeks throughout (158 people), and a third group received adalimumab (159 people). The trial was measuring changes in psoriasis severity using two main scoring tools — a detailed skin assessment called the PASI score (which rates redness, thickness, and scaling across the body on a scale of 0 to 72), and a doctor's overall rating called the IGA (rated 0 to 4, from clear to severe). The trial ran for 56 weeks in total. The reported data shows that at week 16, when the two bimekizumab groups were combined for comparison against adalimumab, 86.2% of bimekizumab participants had at least a 90% improvement in their PASI score, compared with 47.2% in the adalimumab group. For the doctor's overall rating at week 16, 85.3% of bimekizumab participants were rated as "clear" or "almost clear" compared with 57.2% in the adalimumab group. At week 4, 76.5% of the bimekizumab group had at least a 75% improvement in their PASI score versus 31.4% for adalimumab, and by week 16, 60.8% of bimekizumab participants had a complete 100% improvement in their PASI score compared with 23.9% for adalimumab. The reported data also shows that at week 24, results were similar across both bimekizumab dosing schedules — roughly 85–86% of participants in each bimekizumab group had at least a 90% PASI improvement, and around 86–87% were rated "clear" by their doctor, compared with approximately 52% and 58% respectively in the adalimumab group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 36689515) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be at least 18 years old
- You have had chronic plaque psoriasis for at least 6 months before the screening visit
- Your psoriasis is considered moderate to severe, based on specific medical measurements of how much of your body is affected and how severe it looks (confirm with trial site)
- Your doctor has determined that you need a full-body (systemic) treatment or light therapy for your psoriasis
- If you are a woman who could become pregnant, you must be willing to use a highly effective form of birth control during the trial
Who may not be able to join:
- You have a known allergy or sensitivity to the ingredients in either of the study drugs (bimekizumab or adalimumab)
- You currently have an infection (other than a common cold), have had a serious infection, or have a history of infections that keep coming back or are hard to treat
- You currently have or have had hepatitis B, hepatitis C, or HIV
- You have tuberculosis (TB), are at high risk of getting TB, or have had a related type of bacterial infection
- You have another medical or mental health condition that the study doctor believes would make it unsafe or unsuitable for you to participate
- You have previously been treated with the drug adalimumab
- You are currently having thoughts of suicide or self-harm
- You are currently experiencing moderate or severe major depression
- You have had cancer in the last 5 years — except for certain treated and fully cured skin cancers or early-stage cervical cancer
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: UCB Cares, +1 844 599 2273 (UCB)
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16; Percentage of Participants With an Investigator's Global Assessment (IGA) Response (Clear or Almost Clear With at Least 2-Category Improvement Relative to Baseline) at Week 16
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.